A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: A novel topical antibiotic for Staphylococcal infections

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Hu, Yanmin ^a,b   Shamaei Tousi, Alireza ^b   Liu, Yingjun ^b   Coates, Anthony ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b c o Earlsfield Business Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; DAPTOMYCIN; HT 61; LEVOFLOXACIN; LINEZOLID; METICILLIN; PLACEBO; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; TOPICAL ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BROTH DILUTION; CELL DESTRUCTION; CELL MEMBRANE DEPOLARIZATION; CELL PERMEABILIZATION; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA AEROGENES; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MINIPIG; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHENOTYPE; PROPIONIBACTERIUM ACNES; PSEUDOMONAS AERUGINOSA; SEX DIFFERENCE; SKIN TOXICITY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; TOXICITY TESTING; ANIMAL; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCUS INFECTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROSCOPY, ELECTRON, TRANSMISSION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 77955642555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011818     Document Type: Article

References (50)

1. Coates AR, Hu Y (2007) Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 152: 1147-1154.
2. McLeod GI, Spector MP (1996) Starvation- and Stationary-phase-induced resistance to the antimicrobial peptide polymyxin B in Salmonella typhimurium is RpoS (sigma(S)) independent and occurs through both phoP-dependent and - independent pathways. J Bacteriol 178: 3683-3688.
3. Coates AR, Hu Y (2006) New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. Drugs R D 7: 133-151.
4. Tuomanen E (1986) Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 8 Suppl 3: S279-291.
5. Coates A, Hu Y, Bax R, Page C (2002) The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 1: 895-910.
6. Stewart MH, Olson BH (1992) Impact of growth conditions on resistance of Klebsiella pneumoniae to chloramines. Appl Environ Microbiol 58: 2649-2653.
7. Coates AR, Hu Y (2008) Targeting non-multiplying organisms as a way to develop novel antimicrobials. Trends Pharmacol Sci 29: 143-150.
8. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE, Jr. (2004) Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38: 1279-1286.
9. Butler MS, Buss AD (2006) Natural products-the future scaffolds for novel antibiotics? Biochem Pharmacol 71: 919-929.
10. Zappia G, Menendez P, Monache GD, Misiti D, Nevola L, et al. (2007) The contribution of oxazolidinone frame to the biological activity of pharmaceutical drugs and natural products. Mini Rev Med Chem 7: 389-409.
11. Hair PI, Keam SJ (2007) Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 67: 1483-1512.
12. Moellering RC, Jr. (1998) Antibiotic resistance: lessons for the future. Clin Infect Dis 27 Suppl 1: S135-140; discussion S141-132.
13. Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, et al. (2009) Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 53: 918-925.
14. Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167-193.
15. Mitchison DA (1985) The action of antituberculosis drugs in short course chemotherapy. Tubercle 66: 219-225.
16. Kardas P, Devine S, Golembesky A, Roberts C (2005) A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 26: 106-113.
17. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, et al. (2009) A replication clock for Mycobacterium tuberculosis. Nat Med 15: 211-214.
18. Hu Y, Coates AR, Mitchison DA (2003) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 653-657.
19. Kugelberg E, Norstrom T, Petersen TK, Duvold T, Andersson DI, et al. (2005) Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 49: 3435-3441.
20. Mascio CT, Alder JD, Silverman JA (2007) Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 51: 4255-4260.
21. Zierski M (1974) New trends in the chemotherapy of tuberculosis-current aspects. Pneumonologie 150: 1-12.
22. Mitchison DA (2004) Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 25: 307-315.
23. Mitchison DA (2000) Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4: 796-806.
24. Mitchison DA (1979) Basic mechanisms of chemotherapy. Chest 76: 771-781
25. Cuevas O, Cercenado E, Bouza E, Castellares C, Trincado P, et al. (2007) Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: a multicentre prevalence study (2002). Clin Microbiol Infect 13: 250-256.
26. Bradley SF, Ramsey MA, Morton TM, Kauffman CA (1995) Mupirocin resistance: clinical and molecular epidemiology. Infect Control Hosp Epidemiol 16: 354-358.
27. Cookson BD (1998) The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 41: 11-18.
28. Hurdle JG, O'Neill AJ, Mody L, Chopra I, Bradley SF (2005) In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillinresistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother 56: 1166-1168.
29. Yang JA, Park DW, Sohn JW, Yang IS, Kim KH, et al. (2006) Molecular analysis of isoleucyl-tRNA synthetase mutations in clinical isolates of methicillinresistant Staphylococcus aureus with low-level mupirocin resistance. J Korean Med Sci 21: 827-832.
30. Schmitz FJ, Lindenlauf E, Hofmann B, Fluit AC, Verhoef J, et al. (1998) The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 42: 489-495.
31. Coates T, Bax R, Coates A (2009) Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 64: 9-15.
32. Capobianco JO, Doran CC, Goldman RC (1989) Mechanism of mupirocin transport into sensitive and resistant bacteria. Antimicrob Agents Chemother 33: 156-163.
33. Casewell MW, Hill RL (1985) In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 15: 523-531.
34. Wayne LG (1994) Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 13: 908-914.
35. Marks J, Paull A (1990) Multiple breakpoint method for measuring effect of antibiotics on endocarditis strains of streptococci. J Clin Pathol 43: 774-776.
36. Fenollar F, Raoult D (2007) Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents 30 Suppl 1: S7-15.
37. Ellner JJ, Rosenthal MS, Lerner PI, McHenry MC (1979) Infective endocarditis caused by slow-growing, fastidious, Gram-negative bacteria. Medicine (Baltimore) 58: 145-158.
38. del Pozo JL, Serrera A, Martinez-Cuesta A, Leiva J, Penades J, et al. (2006) Biofilm related infections: is there a place for conservative treatment of portrelated bloodstream infections? Int J Artif Organs 29: 379-386.
39. Zegans ME, Becker HI, Budzik J, O'Toole G (2002) The role of bacterial biofilms in ocular infections. DNA Cell Biol 21: 415-420.
40. Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, et al. (1994) Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 32: 1095-1098.
41. Levin ME, Hatfull GF (1993) Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance. Mol Microbiol 8: 277-285.
42. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, et al. (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650.
43. Williams DL, Waguespack C, Eisenach K, Crawford JT, Portaels F, et al. (1994) Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 38: 2380-2386.
44. Yamada T, Nagata A, Ono Y, Suzuki Y, Yamanouchi T (1985) Alteration of ribosomes and RNA polymerase in drug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 27: 921-924.
45. Yates RR (1999) New intervention strategies for reducing antibiotic resistance. Chest 115: 24S-27S.
46. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A (2009) Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 53: 2266-2273.
47. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA (2003) Mupirocinresistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 24: 342-346.
48. Doebbeling BN, Reagan DR, Pfaller MA, Houston AK, Hollis RJ, et al. (1994) Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 154: 1505-1508.
49. Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF (2003) Mupirocinbased decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37: 1467-1474.
50. Wu M, Hancock RE (1999) Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biol Chem 274: 29-35.